CJC 1295 DAC

CJC-1295 Benefits |side effect | DOSAGE |Reviews

CJC-1295 is a peptide hormone that is used as an analog of GHRH (growth hormone releasing hormones),also known as DAC:GRF (short for drug affinity complex:growth hormone-releasing factor) and it has the ability to raise growth hormone and IGF-1, which can give a boost from A to Z, allowing the athlete to reach their fitness goals.Therefore, athletes usually use peptides as part of their stacks in order to enhance their steroid cycles and performance.

BENEFITS & EFFECT

  • anti-aging properties
  • fat loss,
  • lean muscle mass growth
  • injury repair, and better vitality

SIDE EFFECTS

Side effects are very mild and rare on CJC-1295, and they only take place if this compound is abused. When such cases take place, some users complain about numbing fingers/hands, joint aches, and low blood sugar.

Similar Posts

  • Wholesale Price For Best effect IGF In 2022

    What is IGF-1 Lr3  ? IGF–1 is a hormone similar in molecular structure to insulin.It plays an important role in childhood growth and continues to have anabolic effects in adults.A synthetic analog of IGF–1, mecasermin, is used for the treatment of growth failure. What is Igtropin ? Igtropin is a brand of the IGF . benefits and effect of …

  • EPITHALON Pre Mixed Peptide Pen

    Epithalon is also referred to as epithalamion or epothilone. Studies show that this peptide can help with ageing, for its effects for anti-ageing. Its shown as the potent antioxidant which can be antioxidant which can be Epithalon 100mg Pre Mixed Pen Epitalon is a tetrapeptide, implying that it is comprised of 4 amino acid chains….

  • MELANOTAN-2 Pre Mixed Peptide Pen

    Melanotan-II(Melanotan-2 Or MT-2) is a lab-made chemical that is similar to a hormone found in people. Be careful not to confuse melanotan-II with melatonin. Melanotan-II is given as a shot to produce erections in men with ED (erectile dysfunction), tan the skin, and prevent skin cancers caused by sun exposure. MELANOTAN-2 Pre Mixed Peptide Pen…